Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... Rochester, NY (PRWEB) January 14, 2014 During ... is now known as “The Doctor’s Plague.” In this time ... their hands. This led, at times, to the death of ... staff today don’t know that they may be unwittingly transmitting ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
(Date:1/14/2014)... City, Panama (PRWEB) January 14, 2014 ... has received the county’s first clinical trial approval ... umbilical cord-derived mesenchymal stem cells (MSC) from the ... Review Board (IRB). , Rheumatoid Arthritis (RA) is ...
Breaking Biology Technology:Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3BioMedomics, Inc. Closes $690K Round of Financing 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 2Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board 3
... OAB Drug in China, PLYMOUTH MEETING, Pa., ... BJGP ) ("BMP Sunstone" or the "Company") today,announced ... was officially accepted by China,s State Food & ... requirement prior to,pursuing a clinical trial and, ultimately, ...
... Programs Supported by a Grant from Otsuka ... America Pharmaceutical, Inc., ROCKVILLE, ... nonprofit organizations and one individual,as the recipients of the fifth annual ... the 2008 APF Annual Benefit in,Washington, D.C. Each organization or individual ...
... 6 Biomatrica, the leader in room,temperature biological sample ... as Vice President of Sales and Marketing.,Biomatrica,s interim Vice ... integral part of the company and will continue to ... Ms. Dowling brings fourteen years of sales and marketing ...
Cached Biology Technology:BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 2BMP Sunstone Receives SFDA Acceptance for Enablex(R) Clinical Trial 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 2American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 3American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 4American Psychiatric Foundation Announces Recipients of 2008 Awards for Advancing Minority Mental Health 5Trisha Dowling Joins Biomatrica as Vice President, Sales and Marketing 2
(Date:4/23/2014)... pair of bioethics experts have added "playwright" to their ... in grappling with an onslaught of ethical issues as ... the human genome was first sequenced. , Until ... W. Bush have been performed for, and by, their ... conferences, meetings and in classrooms. With Oxford University ...
(Date:4/23/2014)... ripping open a dinner roll, a fuel cell catalyst ... hydrogen molecule. Now researchers have captured a view of ... its hydrogen feast. The view confirms previous hypotheses and ... better for alternative energy uses. , This study is ... hydrogen halves end up in the structure of a ...
(Date:4/23/2014)... source of a unique rhythmic sound, recorded for decades ... the Antarctic minke whale ( Balaenoptera bonaerensis ). First ... who thought it sounded like a duck, the bio-duck ... Southern Ocean, but its source has remained a mystery, ... of researchers deployed acoustic tags on two Antarctic minke ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... from the University of Copenhagen and the Technical University ... the US found that the bacterium Pseudomonas aeruginosa ... white blood cells preventing the bacteria being eliminated ... aeruginosa is responsible for many hospital-acquired infections and ...
... 2009 / b3c newswire /- PlatformQ , ... healthcare, education and energy markets, and LabRoots , a ... that Mark Vachon, the President and CEO for GE Healthcares ... Thursday November 19th at 2:00 PM. GE Healthcare ...
... Rockville, Md. (Oct. 30, 2009) A collaborative research team ... Australian Animal Health Laboratory and National Cancer Institute, a component ... forward in the development of an effective therapy against two ... results of this finding appear Oct. 30, 2009, in the ...
Cached Biology News:Bacteria 'launch a shield' to resist attack 2GE Healthcare President & CEO, Mark Vachon, to Present at BioConference Live 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 2USU scientists report major advance in human antibody therapy against deadly Nipah virus 3
... developed specifically for the stabilization of ... plates/strips. Coating Stabilizer maintains the ... or protein antigen portion of the ... filtered at 0.2 microns., ,Contents: ...
... Novagen's HT96 Isothermal Block is an ... hold HT96 plates and to provide efficient ... plate. This new design of the HT96 ... offers an enhanced product design allowing for ...
Umbilical cord blood neutrophils, For immunohistochemistry (IHC)...
...
Biology Products: